Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
Targeted Oncology1d
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...
Medindia6d
Early Oral Cancer Detection Made Easy With Saliva Test
Discover how a simple saliva test offers a painless and reliable method for early oral cancer detection, potentially ...